Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
Seattle based Shape Therapeutics is aiming to reprogram cells by delivering guide RNAs via AAV - it has partnerships with Otsuka and Roche
Dyno Therapeutics is using AI to develop next generation AAV vectors for gene therapies
Benchling Co-Founder and CEO Sajith Wickramasekara kicks off Benchtalk 2024 and highlights new feature announcements for this software platform that powers the biotech sector
ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis
Innovation Day San Diego: Palm Therapeutics is focused on developing palmitoylation targeted therapies
Innovation Day San Diego: The founder of San Diego based Resolute Science describes how the company aims to use macrophages to deliver toxic payloads to tumors
Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates
Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion
Versant Ventures has built a discovery center in Basel called Ridgeline that helps incubate new companies - it has already resulted in successes you will know
Cambridge UK based Constructive Bio announced a $58 million series A today, one of the largest in the UK region
Gameto CEO Dina Radenkovic talks about running a women's health biotech, the development of Fertilo, work on menopause, and more
Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month
Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously
The CEO of France's Orano Med gives an overview of the radiopharmaceutical approach and why he believes alpha emitters are the way to go
The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use
Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue
Phoenixville, PA based PleoPharma is readying a phase 3 study of its therapy to treat cannabis withdrawal
BaseCure Therapeutics is a Delaware area startup that is working on siRNAs for cardiometabolic diseases like hypertension and obesity
The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more
.png){kind=logo}
